Robert Fisher, MD
Epilepsy · Stanford, CANPI 1669425740
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,475 of the $41,101 with a category attached, or 71.7%. Medtronic accounts for 85.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $19,474 and has fallen 99.5% since, to $91 in 2023. Among epilepsy clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $856.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$35K
- Cochlear Americas$5K
- Biogen$1K
- Boston Scientific$91
Across 18 payments — averaging $23,423 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insightec,ltd$377K
- Eisai Inc.$45K
What the payments were for
- Consulting fees$7,74119%
- Speaking & faculty fees$29,47572%
- Travel & lodging$2,7167%
- Food & beverage$1,1693%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 45 | $35,069 |
| Cochlear Americas | 1 | $4,600 |
| Biogen | 1 | $1,341 |
| Boston Scientific | 1 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,101 in reported general payments places this provider in the 90th percentile of 46 epilepsy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 28 | $31,353 |
| Rufinamide | 12 | $29,744 |
| OnfiClobazam | 22 | $25,702 |
| FycompaPerampanel | 14 | $18,587 |
| XcopriCenobamate | 13 | $14,020 |
| Lacosamide | 39 | $5,290 |
| DilantinPhenytoin Sodium Extended | 14 | $3,531 |
| Clobazam | 24 | $3,477 |
| ValacyclovirValacyclovir Hcl | 12 | $1,424 |
| Lamotrigine | 11 | $897 |
| Phenytoin Sodium Extended | 22 | $807 |
| Lamotrigine ErLamotrigine | 12 | $628 |
| Gabapentin | 18 | $584 |
| Levetiracetam | 13 | $531 |
| Clonazepam | 32 | $472 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Stanford
- Josef ParviziStanford$438K
- Kimford MeadorStanford$50K
- Martha MorrellStanford$17K
- Erica von SteinStanford$2K
- Yi LiStanford$664
- Jessica WalterStanford$157
- Babak RazaviStanford$100
- Kevin GraberStanford$74
- David King StephensOrange$551K
- Mona SazgarOrange$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.